IsoPlexis Names PhenoVista Biosciences a Certified Service Provider
PhenoVista among new certified service providers of IsoPlexis’ functional proteomics platform
San Diego, CA, August 20, 2020 9:00 AM — PhenoVista Biosciences, a California-based company with an unmatched combination of imaging expertise, assay development experience, and the latest technologies and data analysis capabilities, was selected as a Certified Service Provider of IsoPlexis’ products. PhenoVista can now offer the full array of IsoPlexis’ IsoCode and CodePlex assays, single-cell and ultra-small sample volume solutions which accelerate workflows and are of critical use in the study of cancer immunology, infectious diseases, inflammation, vaccine development, and cell and gene therapy research.
PhenoVista helps clients of all sizes from around the world develop and implement imaging-based phenotypic cell assays. The company prides itself on providing clients with broad and versatile expertise in areas such as imaging and assay development, as well as the latest standards in research technology. PhenoVista can now provide IsoPlexis’ single-cell functional proteomics and highly-multiplexed ELISA solutions, allowing its clients to access a comprehensive range of cellular assay technologies.
“We are excited to have named PhenoVista a Certified Service Provider for the IsoPlexis platform,” said Sean Mackay, Chief Executive Officer of IsoPlexis. “We look forward to our unique single-cell proteomics platform being widely accessible through PhenoVista, enabling its use in leading research institutions at the forefront of scientific discovery.”
“We continually strive to provide our clients with the highest quality and most relevant data possible. In partnering with IsoPlexis, we believe that we can extend our already powerful platform to leverage this exciting new microfluidic technology,” said James Evans, PhD, CEO of PhenoVista Biosciences. “Working with IsoPlexis and their highly multiplexed single-cell protein analysis platform beautifully complements our imaging-based readouts providing new insights for our colleagues in the drug development community.”
ABOUT PHENOVISTA BIOSCIENCES:
PhenoVista Biosciences is the leading provider of custom imaging-based phenotypic assay services. With a collaborative and scientifically driven project design and management approach, PhenoVista has a proven track record of delivering high quality data from robust and scalable assays. Phenovista’s key advantage lies in the ability of their industry-trained scientists to combine world-class understanding of diverse biological systems with cutting-edge quantitative imaging to deliver clear, actionable output data. For more information, please visit www.PhenoVista.com.
IsoPlexis (www.isoplexis.com) is dedicated to accelerating the fight against cancer and a range of the world’s toughest diseases with its uniquely correlative, award-winning single-cell proteomics systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage. Our integrated systems, named #1 innovation by the Scientist Magazine & Fierce, are used globally to advance the field of single-cell biology and biomarkers.
VP of Marketing